<DOC>
	<DOCNO>NCT02866006</DOCNO>
	<brief_summary>BVAC-C immunotherapeutic vaccine use B-Cell Monocytes antigen present cell . This study Open-label , dose-escalation , multiple dosing study evaluate safety , tolerability , immune response pre efficacy BVAC-C patient multiple metastatic progressive recurrent HPV type 16 18 positive cervical cancer failure standard care . 9~18 patient enrol</brief_summary>
	<brief_title>Safety Tolerability Evaluation Study BVAC-C Patients With HPV Type 16 18 Positive Cervical Cancer</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<criteria>Patients multiple metastatic progressive recurrent HPV type 16 18 positive cervical cancer Patients receive 1 platinum base doublet chemotherapy prior therapy progressive recurrent tumor lesion ( prior therapy include platinum chemotherapy give radiation therapy 1st line treatment progression recurrence ) Patients least 1 measurable lesion accord RECIST Female patient age 20 70 Patients ECOG performance status 0 2 Patients meet blood test standard screen test ANC≥1500/μL LLN ≤ALC ≤ULN Platelets≥100,000/μL Hemoglobin &gt; 9g/dL Patients meet blood chemistry test standard screen test Serum creatinine ≤ 2.0 mg/dL Calculated creatinine clearance ≥ 50 mL/min Serum bilirubin ≤1.5 x ULN ALT AST ≤2.5 × ULN ( ≤ 5 x ULN patient liver metastasis ) Patients agree medically accept contraceptive clinical trial Patients least three month survival expect Patients decide participate clinical trial sign write informed consent Patients histopathology neuroendocrine small cell carcinoma Patients history brain metastasis sign brain metastasis Patients test positive serological test hepatitis C virus hepatitis B virus surface antigen , ( HBsAg ) human immunodeficiency virus ( HIV ) Patients history HIV infection Patients show abnormal electrocardiogram , include arrhythmia Patients administer drug clinical trial within 4weeks screen visit Patients administer vaccine within 4weeks screen visit ( eg . hepatitis A , hepatitis B , influenza , Td , etc . ) Patients administer blood product within 3 month screen visit Patients receive chemotherapy radiation therapy within 4weeks 1st administration investigational drug ( BVACC ) Patients treat immunosuppressant immunomodulatory agent within 6 month screen visit Patients participate clinical trial therapeutic vaccine immune therapy within 1 year screen visit Patients history serious allergic disease serious side effect drug Patients pregnant breastfeed Patients researcher determine participation clinical trial inappropriate Patients suspect primary cancer</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HPV</keyword>
	<keyword>Type 16 , 18</keyword>
	<keyword>E6E7</keyword>
	<keyword>Immune therapeutic vaccine</keyword>
</DOC>